Novo Nordisk stock jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first ...

The maker of Ozempic and Wegovy expects lower sales and profit growth this year despite recent victories against compounders.

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Drugmaker Novo Nordisk expects a recovery of Wegovy weight-loss drug ...

The diet company formerly known as WeightWatchers has filed for bankruptcy after its 62-year-old business model was put under ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly (LLY) reported first quarter earnings on Thursday, beating Wall Street's expectations on the top and bottom lines, ...

The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.

Wegovy, the popular weight-loss drug from Novo Nordisk, will be available through several leading telehealth providers, ...